Format

Send to

Choose Destination
JAMA Dermatol. 2018 Jul 1;154(7):796-805. doi: 10.1001/jamadermatol.2018.0916.

Whole-Body Distribution and Clinical Association of Telangiectases in Systemic Sclerosis.

Jouvray M1,2,3,4, Launay D1,2,3,4, Dubucquoi S1,2,5, Sobanski V1,2,3,4, Podevin C1,2,4, Lambert M1,2,3,4, Morell-Dubois S3,4, Maillard H3,4, Hatron PY3,4, Hachulla E1,2,3,4, Giovannelli J1,2,3,4.

Author information

1
University Lille, Lille Inflammation Research International Center, Lille, France.
2
Inserm, Lille, France.
3
CHU Lille, Département De Médecine Interne et Immunologie Clinique, Lille, France.
4
Centre de Référence des Maladies Autoimmunes et Systémiques Rares du Nord et Nord-Ouest de France, Lille, France.
5
Institut d'Immunologie, CHU Lille, Institut d'Immunologie, Lille, France.

Abstract

Importance:

In systemic sclerosis (SSc), to date, no study has precisely described the total number and fine distribution of telangiectases (TAs), their clinical association with the disease, and the biological mechanisms causing their development.

Objectives:

To describe the whole-body distribution of TAs and assess the association between the whole-body TA number and the characteristics of patients with SSc.

Design, Setting, and Participants:

A single-center, cross-sectional study was conducted between July 11, 2016, and March 15, 2017, at the National Referral Centre for Rare Systemic and Autoimmune Diseases in France. A population-based sample of 106 adults who fulfilled the 2013 American College of Rheumatology/European League Against Rheumatism criteria for SSc were included; 8 patients who had previously received laser treatment for TAs were excluded.

Main Outcomes and Measures:

The number of TAs on the whole body (total and those >5 mm) and TA distribution in different areas were recorded. The association with clinical and biological data was studied using univariate and multivariate linear regression.

Results:

A total of 106 patients (83 [78.3%] women) were enrolled, including 12 with precapillary pulmonary hypertension (PH). Mean (SD) age was 60.6 (13.5) years. Telangiectasia distribution was 37.2% on the face, 33.2% on the upper limbs, including 26.4% on the hands, 28.1% on the trunk, including 17.1% for the upper part of the trunk, and 1.5% on the lower limbs. In analysis using the multivariate linear regression model, the whole-body TA number was independently associated with male sex (percentage change, 144.4%; 95% CI, 7.5% to 455.9%; P = .03), PH (162.8%; 95% CI, 5.6% to 553.8%; P = .04), history of pulmonary embolism (336.4%; 95% CI, 39.0% to 1270.1%; P = .01), glomerular filtration rate (-1.6%; 95% CI, -3.2% to -0.1% per 1-mL/min/1.73 m2 increase; P = .04), and soluble endoglin level (28.2%; 95% CI, 1.2% to 62.5% per 1-ng/mL increase; P = .04). Receiver operating characteristic analyses assessing the ability of TAs to identify the presence of PH revealed that the area under the curve was significant for the TA number on the whole body (0.77; 95% CI, 0.57 to 0.88), on the hands and face (0.81; 95% CI, 0.57 to 0.91), and on the hands (95% CI, 0.77; 95% CI, 0.57 to 0.89).

Conclusions and Relevance:

In the patients in this study with SSc, TAs were predominantly located on the face, hands, and the upper part of the trunk. Telangiectases appeared to be associated with vasculopathy features of SSc, particularly with PH and soluble endoglin levels.

PMID:
29799952
PMCID:
PMC6128493
[Available on 2019-05-16]
DOI:
10.1001/jamadermatol.2018.0916

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center